Addiction Treatment: Catalyst Pharma: Cocaine-Addiction Drug Candidate Didn’t Meet Primary Endpoint – Wall Street Journal
Catalyst Pharma: Cocaine-Addiction Drug Candidate Didn’t Meet Primary Endpoint – Wall Street Journal
Filed under: Addiction Treatment
|
Catalyst Pharma: Cocaine-Addiction Drug Candidate Didn't Meet Primary Endpoint
Wall Street Journal Catalyst Pharmaceutical Partners Inc. (CPRX) said its potential cocaine addiction treatment, CPP-109, didn't meet the primary endpoint of a Phase II(b) study. Shares dropped 62% to 55 cents premarket as the pharmaceutical company said CPP-109, … Catalyst Pharma' PhaseII cocaine Addiction trial fails to meet primary end point Catalyst Pharma shares collapse after addiction drug flops in PhIIb |
Addiction Treatment – Google News
Find More Addiction Treatment Information…